Gentry Patrick R., Kokubo Masaya, Bridges Thomas M., Daniels J. Scott, Niswender Colleen M., Smith Emery, Chase Peter, Hodder Peter S., Rosen Hugh, Conn P. Jeffrey, Engers Julie, Brewer Katrina A., Wood Michael R., Lindsley Craig W.
Vanderbilt University
Scripps Research Institute
A recently completed functional, high throughput screen of the Molecular Libraries Probe Production Center's Network (MLPCN) screening deck of ∼360,000 compounds conducted by Scripps Research Institute Molecular Screening Center (SRIMSC) against three of the five muscarinic receptor subtypes (M, M and M) provided a number of interesting hits. As this was the first time a directed effort had been undertaken to identify M selective leads, we were very pleased by the identification of nine M PAMs and nine M antagonists (or negative allosteric modulators, NAMs), despite the complete absence of M agonist hits. The most promising M inhibitor hit (CID 5189681), was quickly developed into a potent, selective and CNS penetrant probe molecule ML375 (hM NAM IC = 300 nM, hM ICs >30 μM) displaying enantioselective inhibition. Detailed molecular pharmacology studies demonstrated that ML375 is the first M NAM ever described, and ML375 show good rat and cyno pharmacokinetics to support studies in rodents and non-human primates.